Literature DB >> 515498

Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans.

A M Shepherd, T M Ludden, K D Haegele, T Talseth, J L McNay.   

Abstract

Hydralazine is an antihypertensive vasodilator agent. Lack of specific assay techniques for its measurement have delayed elucidation of its pharmacokinetic profile. This study compares the plasma profiles of hydralazine, measured both by a specific and by a previously published nonspecific assay and of a major plasma metabolite, hydralazine pyruvic acid hydrazone. After po and iv administration of hydralazine, peak hydralazine levels were lower (7-33%) and plasma half lives were shorter (15-31%) when measured by the specific technique. The mean plasma half life of the pyruvic acid hydrazone was 156 min and mean urinary clearance, 28 ml/min. The plasma profile of hydralazine and of the major metabolite, the pyruvic acid hydrazone, do not appear to correspond to the duration of antihypertensive effect of administered hydralazine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 515498

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  4 in total

Review 1.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

2.  Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.

Authors:  Lyrialle W Han; Rachel J Ryu; Michael Cusumano; Thomas R Easterling; Brian R Phillips; Linda J Risler; Danny D Shen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2019-06-30       Impact factor: 3.126

3.  Pharmacokinetics of oral hydralazine in chronic heart failure.

Authors:  A Hanson; B W Johansson; B Wernersson; L A Wåhlander
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Altered blood pressure response to propyldazine after repeated oral administration in conscious normotensive dogs: role of the renin-angiotensin system.

Authors:  S Bacher; O Kraupp; A Beck; R Seitelberger; G Raberger
Journal:  Basic Res Cardiol       Date:  1984 Sep-Oct       Impact factor: 17.165

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.